Sanofi (NASDAQ:SNY – Free Report) had its target price raised by Argus from $55.00 to $60.00 in a report issued on Friday morning, Marketbeat Ratings reports. Argus currently has a buy rating on the stock.
Sanofi Stock Down 0.6 %
Shares of Sanofi stock opened at $52.09 on Friday. Sanofi has a twelve month low of $42.63 and a twelve month high of $55.72. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 0.17. The company’s 50 day moving average is $49.29 and its 200 day moving average is $48.66. The company has a market cap of $131.93 billion, a price-to-earnings ratio of 26.18, a price-to-earnings-growth ratio of 1.63 and a beta of 0.59.
Sanofi (NASDAQ:SNY – Get Free Report) last announced its earnings results on Thursday, July 25th. The company reported $0.93 earnings per share for the quarter, beating analysts’ consensus estimates of $0.88 by $0.05. The business had revenue of $10.75 billion during the quarter, compared to analyst estimates of $16.86 billion. Sanofi had a net margin of 9.60% and a return on equity of 26.29%. The company’s quarterly revenue was up 7.8% compared to the same quarter last year. During the same period in the previous year, the business earned $0.95 EPS. Research analysts anticipate that Sanofi will post 4.14 EPS for the current year.
Institutional Investors Weigh In On Sanofi
About Sanofi
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.
Read More
- Five stocks we like better than Sanofi
- How to Capture the Benefits of Dividend Increases
- Survey: Top 175 Fittest Retirement Locations in America
- Best Stocks Under $5.00
- Kimberly-Clark Stock Dips and a Buying Opportunity Emerges
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Leading Gold Stock Shines With Q2 2024 Earnings Release
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.